Established in 2001, Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. was invested in and founded by four shareholders, namely, Charoen Pokphand Group, Chia Tai Tianqing, Jiangsu Provincial Agricultural Reclamation and Development Co., Ltd. and Nanjing Jinkang. Now, with its products covering the five major therapeutic fields - cardiovascular and cerebrovascular diseases, tumors, perioperative management in surgical departments, digestion and urology - it has ranked among the Top 100 Companies in the Chinese Pharmaceutical Industry which engages in "the R&D, production and sales of pharmaceuticals."

Oriented by R&D and driven by innovation. Adhering to an R&D philosophy of “innovation driven by generic drug development, ushering in the future” the company relies on its R&D investment (which is several times higher than the industry average) and its R&D team of more than 360 experts to create its core products, which rank among the first batch of generic drugs in China that have passed consistency evaluations. At present, there are more than 100 products under research, including innovative drugs, sustained and controlled-release prescriptions, characteristic generic drugs, etc. This, coupled with the approved operation of postdoctoral workstations, innovative vitality has been continuously injected into the company's development.

Promoted by marketing and accelerated by competition. Since the company began operations, its average annual compound growth rate of sales has reached 33%, far exceeding the industry average. It has formed a laddered cluster of products supported by groups of products worth over 100 million Chinese Yuan, which are geared towards treating “chronic diseases and tumors”, and paying equal attention to oral and injection forms. In addition, a three-level academic promotion system is utilized, comprising more than 2,000 people engaging in professional academic promotions, involving the two major markets of "hospitals and pharmacies", and taking the marketing and medical departments as its core. Its core products have taken the lead in the sub-segments of cardiovascular and cerebrovascular diseases, tumors, and perioperative management in surgical department, etc.

Accumulating strength and achieving glory. After over a decade of development, the company has embarked on the road of "being driven by both R&D and marketing". With the expansion of its industrial chain to the upstream active pharmaceutical ingredients (APIs), and its extension to the downstream comprehensive management of diseases and the high-quality products brought about by scientific and standardized management and intelligent manufacturing - which continuously promote the company's healthy, sustainable and rapid development - the company has been successively awarded the “Key High-tech Enterprise of National Torch Plan”, “China Scientific and Technological Innovation Outstanding Enterprise”, “National Pharmaceutical Quality and Integrity Demonstration Enterprise”, “Jiangsu Province May 1st Labor Award”, and the “Jiangsu Province Demonstration Enterprise of the Integration of Informationization and Industrialization”, etc.

Embracing the future and making new progress. With the all-round use of its new pharmaceutical industrial park, integrating “R&D, production, management and training”, in which a total of more than 2 billion Chinese Yuan has been invested, the company is set to achieve its strategic goal of “one center and three platforms” (i.e., building an intensive strategic headquarters, creating three platforms respectively for the intellectual promotion of R&D, intellectual creation of formulations and intellectual efficiency of APIs) realized in an all-round way. Nanjing Chia Tai Tianqing is going to be a first-class R&D and manufacturing enterprise of cardiovascular and cerebrovascular pharmaceuticals in China, and it will also make great achievements in the fields of tumors, psychiatry and perioperation.